*3.3. Survival Analysis*

Initial cMRI evaluation was performed. During a median follow-up of 17 months (IQR 1 to 29 months), 31 patients (17.4%) experienced MACEs: VA (*n* = 14), HF requiring hospitalization (*n* = 11), and SCD (*n* = 6). The patients with VA were majority males, had increased LVESV (mean 107,533 mL, *p* < 0.001), decreased LVEF (28,429%, *p* < 0.0001), increased LGE mass (24,5 g, *p* < 0.0001) and LVSI (0.46, *p* < 0.001). Of them, ten received ICD therapy and 4 were ablated due to implantable cardioverter defibrillator therapy refusal, the last had a mean LVEF around 30%, two of them had NIDCM post-myocarditis and two were idiopathic NIDCM. The incidence of MACEs was significantly higher in the LGE+ group vs. the LGE− group (*n* = 21, 67.7% vs. *n* = 10, 33.4%). The Kaplan-Meier curves for event-free survival showed a significantly higher rate of MACEs in patients with LGE+ (HR = 4.02; 95%CI (1.91–8.45), *p* < 0.001), high LVSI (HR = 3.23; 95%CI (1.59–6.53), *p* < 0.01) and decreased LAS (HR = 3.94; 95%CI (1.93–8.03), *p* < 0.001) (Figure 3).
